[Use of erythropoietin in the treatment of patients with oncohematological diseases].
The role of erythropoietin in the development of anemia in patients with oncohematological diseases has been discussed. Efficacy of use of erythropoietin in patients with oncohematological diseases was analyzed. Features of use, contraindication and adverse reactions have been discussed. Erythropoietins-beta have proved to be more effective than erythropoietins-alpha.
Lysenko
D A
DA
Lutsenko
O M
OM
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications*; D006801:Humans; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin